AstraZeneca (LON:AZN) Cut to Buy at Citigroup

AstraZeneca (LON:AZN) was downgraded by equities researchers at Citigroup to a “buy” rating in a research note issued on Friday,London Stock Exchange reports.

Other research analysts have also issued reports about the company. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 target price on shares of AstraZeneca in a research report on Friday, June 26th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a report on Friday, June 26th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of £153.33.

AstraZeneca Trading Down 1.6%

Shares of LON:AZN opened at £131.34 on Friday. The business’s fifty day simple moving average is £137.31 and its 200-day simple moving average is £141.54. AstraZeneca has a 12-month low of £101.78 and a 12-month high of £157.32. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66. The company has a market capitalization of £203.69 billion, a PE ratio of 19.78, a P/E/G ratio of 0.86 and a beta of 0.23.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.